Flemington, NJ, United States of America

Aleksey I Gerasyuto

This inventor holds 25 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Integrin Inhibitors. Top assignees: Morphic Therapeutic, Inc., Hibercell, Inc., Ptc Therapeutics, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aleksey I Gerasyuto. Retrieved from https://idiyas.com/inventor/aleksey-i-gerasyuto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 13)

% Patents Active = 96.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 11 (Patent Applications = 18)

Average Co-Inventor Count = 12.8

ph-index = 5

Forward Citations = 66(Granted Patents)

Company Filing History:

17 out of 17

Morphic Therapeutic, Inc.

Ptc Therapeutics, Inc.

patents

4. 1 out of 11

Mmv Medicines for Malaria Venture

patents

5. 1 out of 4

Petra Pharma Corporation

patents

6. 1 out of 5,640

The University of Texas System

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Integrin Inhibitors

Phosphatidylinositol Kinase

Anti-Malarial Agents

Huntington's Disease

Aryl-Bipyridine

Heterocyclic Compounds

Allosteric Inhibitors

Antibacterial Compounds

Chromenopyridine

Aminopyridine Derivatives

Antagonists

Disease Treatment

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12552786 - Inhibitors of αvβ6 integrin (2026-02-17),

2. 12528803 - Inhibitors of αvβ6 integrin (2026-01-20),

3. 12459942 - Inhibiting (α-v)(β-6) integrin (2025-11-04),

4. 12415796 - Inhibitors of (αv)(β6) integrin (2025-09-16),

5. 12221416 - Antagonists of human integrin α4β7 (2025-02-11),

6. 12145935 - Inhibitors of (α-v)(β-6) integrin (2024-11-19),

7. 11919902 - Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors (2024-03-05),

8. 11903936 - Anti-malarial agents (2024-02-20),

9. 11858941 - Heterocyclic and heteroaryl compounds for treating Huntington's disease (2024-01-02),

10. 11827621 - Inhibitors of (α-v)(β-6) integrin (2023-11-28),

11. 11795167 - Inhibitors of (α-v)(β-6) integrin (2023-10-24),

12. 11739087 - Inhibiting (α-v)(β-6) integrin (2023-08-29),

13. 11667651 - Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors (2023-06-06),

14. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2023-05-16),

15. 11584763 - Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors (2023-02-21),

Title: The Innovative Mind of Aleksey I. Gerasyuto

Introduction: Aleksey I. Gerasyuto, based in Flemington, NJ, has made significant contributions to the field of biomedical research and pharmacology. With a remarkable portfolio of 21 patents, he has played a vital role in developing novel therapeutic approaches aimed at addressing specific diseases and conditions.

Latest Patents: Gerasyuto's latest patents include groundbreaking work on antagonists of human integrin α4β7. These small molecule antagonists exhibit potential in treating various diseases by modulating the immune response. Additionally, he has developed inhibitors of αvβ6 integrin, which also focus on innovative methods for treating a range of health conditions. Both patents underscore his commitment to advancing medical science through targeted drug discovery and development.

Career Highlights: Throughout his career, Gerasyuto has collaborated with leading biopharmaceutical companies including Morphic Therapeutics, Inc. and PTC Therapeutics, Inc. His time at these organizations has allowed him to further refine his expertise in integrin biology and drug development, positioning him as a respected innovator in the industry.

Collaborations: Gerasyuto has worked closely with notable colleagues such as Fu-Yang Lin and Blaise S. Lippa. These collaborations have not only enhanced his research capabilities but have also contributed to the successful advancement of innovative therapeutic strategies and the patenting of novel inventions.

Conclusion: Aleksey I. Gerasyuto's innovative work and extensive patent portfolio reflect his dedication to advancing medical research and therapeutic innovation. By constantly developing and patenting new methods and compounds, he continues to make a substantial impact in the pharmaceutical industry, addressing unmet medical needs and opening doors for future advancements.

Profile summary based on public USPTO records.